Stock Scorecard



Stock Summary for Ensysce Biosciences Inc (ENSC) - $0.40 as of 5/5/2026 10:16:27 PM EST

Total Score

11 out of 30

Safety Score

15 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ENSC

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ENSC

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ENSC

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ENSC

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ENSC (15 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for ENSC

Ensysce CEO outlines abuse-resistant opioid approach in Amsterdam 5/8/2026 12:01:00 PM
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam 5/8/2026 11:39:00 AM
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam 5/8/2026 11:39:00 AM
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com 4/17/2026 4:09:00 AM
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com 4/16/2026 3:39:00 PM
Ensysce Biosciences Secures IRB Approval for Final Phase of Clinical Study 4/16/2026 1:39:00 PM
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com 4/16/2026 12:39:00 PM
Opioid with built-in overdose safeguard enters final study stage 4/16/2026 11:39:00 AM
[EFFECT] Ensysce Biosciences, Inc. SEC Filing 4/16/2026 4:39:00 AM
ENSC Forecast, Price Target & Analyst Ratings | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) 4/10/2026 2:40:00 PM

Financial Details for ENSC

Company Overview

Ticker ENSC
Company Name Ensysce Biosciences Inc
Country N/A
Description Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/12/2026

Stock Price History

Last Day Price 0.40
Price 4 Years Ago 135.00
Last Day Price Updated 5/5/2026 10:16:27 PM EST
Last Day Volume 159,128
Average Daily Volume 267,560
52-Week High 2.75
52-Week Low 0.31
Last Price to 52 Week Low 29.03%

Valuation Measures

Trailing PE N/A
Industry PE 131.76
Sector PE 81.50
5-Year Average PE -357.64
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio 18.87
Sector Free Cash Flow Ratio 24.59
Current Ratio Most Recent Quarter 1.59
Total Cash Per Share 464,587.94
Book Value Per Share Most Recent Quarter 0.70
Price to Book Ratio 1.10
Industry Price to Book Ratio 18.90
Sector Price to Book Ratio 9.97
Price to Sales Ratio Twelve Trailing Months 0.76
Industry Price to Sales Ratio Twelve Trailing Months 8.86
Sector Price to Sales Ratio Twelve Trailing Months 4.70
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 9,277,800
Market Capitalization 3,711,120
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.40%
Reported EPS 12 Trailing Months -4.36
Reported EPS Past Year -4.22
Reported EPS Prior Year -3.60
Net Income Twelve Trailing Months -10,176,127
Net Income Past Year -10,175,700
Net Income Prior Year -7,987,000
Quarterly Revenue Growth YOY 44.40%
5-Year Revenue Growth 5.21%
Operating Margin Twelve Trailing Months -147.80%

Balance Sheet

Total Cash Most Recent Quarter 4,310,354,000,000
Total Cash Past Year 4,310,354,000,000
Total Cash Prior Year 3,502,077
Net Cash Position Most Recent Quarter 4,310,353,612,824
Net Cash Position Past Year 4,310,353,145,303
Long Term Debt Past Year 854,697
Long Term Debt Prior Year 4,717,104
Total Debt Most Recent Quarter 387,176
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.89
Total Stockholder Equity Past Year 3,213,720,000,000
Total Stockholder Equity Prior Year 3,708,422
Total Stockholder Equity Most Recent Quarter 3,213,720

Free Cash Flow

Free Cash Flow Twelve Trailing Months -8,053,575
Free Cash Flow Per Share Twelve Trailing Months -0.87
Free Cash Flow Past Year -7,806,292,123,643
Free Cash Flow Prior Year -7,502,700,000,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.17
20-Day Bollinger Middle Band 0.61
20-Day Bollinger Upper Band 1.05
Beta 0.88
RSI 36.95
50-Day SMA 8.60
150-Day SMA 0.00
200-Day SMA 146.50

System

Modified 5/8/2026 10:14:14 PM EST